MedPage Today on MSN
PSMA-PET cuts need for biopsy in suspected prostate cancer
But does it cost too much?
AI-assisted imaging improved prostate cancer diagnosis and biopsy decision-making in new research presented at EAU 2026.
A new immunotherapy drug has demonstrated early promise in a recent prostate cancer clinical trial. The drug, called VIR-5500 ...
PHOENIX — Prostate cancer is one of the most common cancers in the world. While many prostate cancers grow slowly and remain localized, other types are aggressive and spread quickly. That's why Dr.
(NYSE: PFE) today announced positive topline results from the Phase 3 TALAPRO-3 study of TALZENNA ® (talazoparib), an oral poly ADP-ribose polymerase (PARP) inhibitor, in combination with XTANDI ® ...
Discover six prostate cancer companies advancing the next generation of therapies for all stages of the disease.
Prostate cancer is one of the leading causes of cancer-related death in men, and some experts project the number of cases to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results